Certolizumab added to chemo and nivolumab for operable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether adding certolizumab (an immune-targeting medicine) to standard chemo plus nivolumab can improve outcomes in people with certain operable non-small cell lung cancers. The goal is to see if this combination works better than standard treatment before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have untreated stage II–III non-small cell lung cancer that a thoracic surgeon says is operable and can be removed with surgery
- Your cancer diagnosis has been confirmed with pathology (biopsy/tissue test) at the study site
- You are age 18 or older and can do daily activities fairly well (Karnofsky score 70 or higher)
- Your blood counts and organ function (bone marrow, liver, and kidneys) meet specific lab cutoffs
- Your cancer has at least one measurable spot on scans, and you can sign consent
- Screening tests show no active tuberculosis, and you can meet pregnancy/birth-control rules if relevant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests combining tumor ablation with the immunotherapy drug tislelizumab and chemotherapy before surgery for people with stage II–IIIB non-small cell lung cancer. The goal is to see if this combination helps remove the cancer more effectively.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.